IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq: SVA) concerning possible violations of federal securities laws.
If you purchased shares of Sinovac and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
The investigation focuses on whether Sinovac and certain of its officers and/or directors violated federal securities laws. On December 21, 2016, SeekingAlpha.com published an article revealing that its Chairman and CEO Weidong Ying paid bribes to an official of the China Food and Drug Administration, in order to help advance drug applications and evaluations. On May 16, 2017, Sinovac announced that the Securities and Exchange Commission is conducting an enforcement investigation related to the bribery discussed in the article, and that the Company would not be able to timely file its annual financial results.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.